Shilpa Medicare received USFDA Establishment Inspection Report on October 24 for the finished dosage formulations facility (sterile and non-sterile dosage forms) located at Pharmaceutical Formulations SEZ, APIIC, Jadcherla, Telangana. The company’s finished dosage form facility was inspected by the USFDA from August 29 to September 5.
The USFDA has concluded that the inspection classification of this facility was “voluntary action indicated”. This facility is in acceptable state of compliance with regard to current good manufacturing practices, it said. Shares of Shilpa Medicare closed at ₹268.10, down 2.47 per cent from its previous close on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.